Skip to Content

UK Edition. Click here for US version.

CANUSAL 100 I.U./ML FLUSHING SOLUTION FOR MAINTENANCE OF PATENCY OF INTRAVENOUS DEVICES

Active substance(s): HEPARIN

View full screen / Print PDF » Download PDF ⇩
Transcript
PACKAGE LEAFLET: INFORMATION FOR THE USER
CANUSAL 100 I.U./ml FLUSHING SOLUTION FOR MAINTENANCE OF
PATENCY OF INTRAVENOUS DEVICES
HEPARIN SODIUM
Read all of this leaflet carefully before you are given this medicine.
- Keep this leaflet. You may need to read it again while you are receiving your treatment.
- If you have any further questions, please ask your doctor or nurse.
- This medicine has been prescribed for you. It should not be shared with other patients.
The name of your medicine is Canusal 100 I.U./ml flushing solution for maintenance of
patency of intravenous devices. In the rest of this leaflet it is called Canusal.
In this leaflet:
1. What Canusal is and what it is used for
2. Before you use Canusal
3. How to use Canusal
4. Possible side effects
5. How to store Canusal
6. Further information
1. WHAT CANUSAL IS AND WHAT IT IS USED FOR
Canusal is heparinised saline which is heparin dissolved in a salt water solution.
Heparin is an anti-clotting agent and is produced naturally in the body. Canusal is used to
wash and rinse the inside of intravenous catheters and cannulas (surgical forms of tubing) to
ensure they do not become blocked while they are in use.
2. BEFORE YOU USE CANUSAL
Do not use Canusal if:
• you have been told you are allergic to heparin.
Pregnancy and breast-feeding
Do not use Canusal if you are pregnant or trying to become pregnant without talking to your
doctor first
Do not use Canusal if you are breast-feeding without talking to your doctor.
If you have any doubts about whether Canusal should be used for you then discuss things
more fully with your doctor or nurse.
3. HOW TO USE CANUSAL
• Canusal should not be injected directly into the body.
• Canusal is used for cleaning catheters and cannulas (surgical forms of tubing) by flushing
with 2ml (200 units) every four hours or as required.
• The doctor will decide which dose is best to be used.
• If blood for tests are to be taken from the tubing which has been rinsed with this product,
the heparin in the tubing should first be withdrawn and discarded.
• Aseptic techniques should be used at all times during its use to avoid contamination.
• Your doctor will check your blood if you use Canusal for longer than five days.
4. POSSIBLE SIDE EFFECTS
Like many medicines Canusal may cause side effects in some patients, although not
everybody gets them, particularly when treatment is first started.
• It can cause bleeding and occasionally a serious blood disorder (thrombocytopenia)

which can cause thrombosis (clotting in the blood vessels).
• Rarely, allergic reactions can occur.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. You can also report side effects directly via the
Yellow Card Scheme www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this
medicine.
5. HOW TO STORE CANUSAL
Keep this medicine out of the reach and sight of children.
• The medicine should not be used if the expiry date on the ampoule has passed. The expiry
date refers to the last day of the month.
• Do not use if the contents of the ampoule show signs of deterioration such as
discolouration.
• This medicine should not be stored above 25ºC.
• Store in the original package in order to protect from light.
• Any portion of the contents not used at once should be discarded.
Medicines should not be disposed of via wastewater or household waste.
Ask your pharmacist how to dispose of medicines no longer required. These measures will
help to protect the environment.
6. FURTHER INFORMATION
What Canusal contains
Canusal is heparinised saline which is heparin dissolved in a salt water solution. It is
available as a sterile heparinised saline flush solution in one strength of 100 international
units per ml. Each 2ml ampoule contains 200 international units of heparin sodium.
The active ingredient in Canusal is heparin sodium. Other ingredients are sodium chloride,
water for injections, hydrochloric acid and sodium hydroxide.
What Canusal looks like and the contents of the pack
Canusal is a colourless or straw-coloured liquid. The registered pack size is 10 glass
ampoules.
X-PIL Information
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of
charge:
0800 198 5000 (UK Only)
Please be ready to give the following information:
Product Name
Canusal 100I.U./ml Flushing Solution

Reference Number
29831/0111

This is a service provided by the Royal National Institute of the Blind.
Marketing Authorisation holder and Manufacturer

Marketing Authorisation holder: Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF,
UK
Manufacturer: CP Pharmaceuticals Ltd, Ash Road North, Wrexham, LL13 9UF, UK.
This leaflet was last revised in 09/2015

1 NAME OF THE MEDICINAL PRODUCT
Canusal 100 I.U./ml flushing solution for maintenance of patency of intravenous devices
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Heparin sodium 100 I.U./ml (200 I.U. in 2ml)
For excipients see 6.1
3 PHARMACEUTICAL FORM
Flushing solution for maintenance of patency of intravenous devices
A colourless or straw coloured liquid, free from turbidity and from matter that deposits on
standing.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Heparin is an anticoagulant and acts by potentiating the naturally occurring inhibitors of
thrombin and factor X (Xa).
Canusal is indicated in any clinical circumstances in which it is desired to flush an
intravenous catheter or cannula with a low concentration of heparin to ensure patency prior
to administration of an intravenous injection.
4.2 Posology and method of administration
Not recommended for systemic use.
For cleaning indwelling cannulae.
Material to be used as an intravascular cannula or catheter flush in doses of 200 units every
4 hours or as required.
4.3 Contraindications
Do not use when there is established hypersensitivity to heparin.
4.4 Special warnings and precautions for use
Caution should be exercised in patients with known hypersensitivity to low molecular weight
heparins.
Rigorous aseptic technique should be observed at all times in its use.
Platelet counts should be measured in patients receiving heparin flushes for longer than five
days (or earlier in patients with previous exposure to heparin). In those who develop
thrombocytopenia or paradoxical thrombosis, heparin should immediately be eliminated
from all flushes and ports.
Repeated flushing of a catheter device with heparin may result in a systemic anticoagulant
effect.
4.5 Interaction with other medicinal products and other forms of interactions
When an indwelling device is used for repeated withdrawal of blood samples for laboratory
analyses and the presence of heparin or saline is likely to interfere with or alter results of the
desired blood tests, the in situ heparin flush solution should be cleared from the device by
aspirating and discarding a volume of solution equivalent to that of the indwelling
venipuncture device before the desired blood sample is taken.
4.6 Pregnancy and lactation

The safety of Canusal in pregnancy is not established, but the dose of heparin involved
would not be expected to constitute a hazard.
Heparin does not appear in breast milk.
4.7 Effects on ability to drive and use machines
None stated.
4.8 Undesirable effects
Used as directed, it is extremely unlikely that the low levels of heparin reaching the blood will
have any systemic effect. However, there have been rare reports of immune-mediated
thrombocytopenia and thrombosis in patients receiving heparin flushes (see also Section
4.4, Special Warnings and Precautions for Use).
Hypersensitivity reactions to heparin are rare. They include urticaria, conjunctivitis, rhinitis,
asthma, cyanosis, tachypnoea, feeling of oppression, fever, chills, angioneurotic oedema
and anaphylactic shock.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/ risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the Yellow
Card Scheme at www.mhra.gov.uk/yellowcard.
4.9 Overdose
Not applicable
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Canusal, containing only 200 I.U. of sodium heparin per ampoule (2ml), is used for flushing
indwelling cannulae. This is unlikely to produce blood levels of heparin having any systemic
effect.
5.2 Pharmacokinetic properties
None stated
5.3 Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are additional to those
already included in other sections.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sodium chloride
Water for injections
Hydrochloric acid 3M
Sodium hydroxide 3M
6.2 Incompatibilities
Heparin and reteplase are incompatible when combined in solution.
Amikacin sulphate, gentamicin sulphate, netilmicin sulphate, pethidine hydrochloride,
promethazine hydrochloride and tobramycin sulphate.
If reteplase and heparin are to be given through the same line this, together with any Y-lines,
must be thoroughly flushed with a 0.9% saline or a 5% glucose solution prior to and following
the reteplase injection.

6.3 Shelf life
Unopened – 36 months
From a microbiological point of view, unless the method of opening precludes the risk of
microbial contamination, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the responsibility of the
user.
6.4 Special precautions for storage
Do not store above 25°C
Store in the original package
6.5 Nature and contents of container
2ml clear glass ampoules
6.6 Special precautions for disposal
Not applicable
7 MARKETING AUTHORISATION HOLDER
Wockhardt UK Ltd
Ash Road North
Wrexham
LL13 9UF
UK.
8 MARKETING AUTHORISATION NUMBER(S)
PL 29831/0111
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 11 September 2007
10 DATE OF REVISION OF THE TEXT
September 2015

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide